By: IPP Bureau
Last updated : August 17, 2026 12:48 pm
The company aims to help pharmaceutical companies improve operational productivity while allowing scientific teams to focus on higher-value activities\
Tata Consultancy Services (TCS) has launched TCS ADD AgentHub, a role-based, enterprise-ready AI platform designed to enable pharmaceutical companies to deploy agentic artificial intelligence across drug development and pharmacovigilance at scale.
Built on the TCS ADD framework, the platform is designed to address challenges faced by pharmaceutical companies in adopting AI within highly regulated environments, including data fragmentation, growing information volumes, governance requirements and increasing regulatory expectations across clinical development and drug safety.
TCS ADD AgentHub enables AI agents to operate within defined roles and oversight frameworks, with built-in auditability and governance. Pharmaceutical companies can configure their own AI agent hubs and deploy them across clinical and safety workflows, with the platform supporting rapid integration while maintaining regulatory and compliance requirements.
According to TCS, solutions powered by the platform have demonstrated up to 40% efficiency gains in clinical data management, while metadata-driven automation can reduce clinical study build efforts by up to 30%.
The company said the platform can also deliver up to 30% cost savings in end-to-end safety case processing, while AI-powered safety agents can reduce quality-control effort by as much as 50%.
The platform is built around a Human + AI Operating Model, in which AI agents are embedded into enterprise workflows while humans retain responsibility for governance, oversight and decision-making.
Debashis Ghosh, President, Lifesciences and Healthcare, TCS, said the platform would enable customers to accelerate drug development using agentic AI at scale while moving operations from reactive models towards more proactive, scalable and audit-ready processes.
TCS ADD AgentHub supports a range of workflows across clinical development and pharmacovigilance. These include Individual Case Safety Report (ICSR) intake, data entry, coding, review and literature analysis; study design and protocol digitisation; clinical data review; SDTM transformation; and medical monitoring assistance.
The platform also features an evolving catalogue of AI agents that can be deployed progressively based on an organisation’s requirements and technology landscape.
The launch comes as pharmaceutical companies increasingly explore agentic AI to automate complex R&D workflows while balancing the technology’s potential with stringent requirements around regulatory compliance, data governance, traceability and human oversight.